US4844119A
(en)
*
|
1988-11-21 |
1989-07-04 |
Allied-Signal Inc. |
Integrated three-way and isolation solenoid valve
|
EP0615451B1
(en)
*
|
1992-05-26 |
2005-12-07 |
Immunex Corporation |
Novel cytokine that binds cd30
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US20030040467A1
(en)
*
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US6936439B2
(en)
*
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US7070771B1
(en)
|
1996-12-09 |
2006-07-04 |
Regents Of The University Of California |
Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
|
CA2693296C
(en)
*
|
1997-12-08 |
2013-09-10 |
Merck Patent Gmbh |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
WO1999040187A1
(de)
*
|
1998-02-06 |
1999-08-12 |
Hinrich Abken |
Nukleinsäuren zur modulation zellulärer aktivierung
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
EP1073734B1
(en)
*
|
1998-04-15 |
2009-09-23 |
Ludwig Institute for Cancer Research Ltd. |
Tumor associated nucleic acids and uses therefor
|
US7001999B1
(en)
|
1998-04-15 |
2006-02-21 |
Ludwig Institute For Cancer Research |
Tumor associated nucleic acids and uses therefor
|
ES2267263T3
(es)
*
|
1998-04-15 |
2007-03-01 |
Emd Lexigen Research Center Corp. |
Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
|
US6245525B1
(en)
*
|
1998-07-27 |
2001-06-12 |
Ludwig Institute For Cancer Research |
Tumor associated nucleic acids and uses therefor
|
KR100719202B1
(ko)
*
|
1998-10-23 |
2007-05-16 |
키린-암젠 인코포레이티드 |
MPl 수용체에 결합하는 화합물 및 이를 함유하는 제약학적 조성물
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7304150B1
(en)
*
|
1998-10-23 |
2007-12-04 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
DE60035871T2
(de)
*
|
1999-05-19 |
2008-06-05 |
Merck Patent Gmbh |
Expression und export von interferon-alpha proteinen als fc fusionsproteine
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
CA2349406C
(en)
*
|
1999-09-03 |
2011-01-11 |
Amgen Inc. |
Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
|
EP1228214A2
(en)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietin forms with improved properties
|
US6808902B1
(en)
*
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
CA2395408A1
(en)
*
|
1999-12-08 |
2001-06-04 |
Amgen, Inc. |
Interferon-like molecules and uses thereof
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
AU5574001A
(en)
*
|
2000-04-25 |
2001-11-07 |
Immunex Corp |
Method for treatment of tumors using photodynamic therapy
|
CA2407956A1
(en)
*
|
2000-05-03 |
2001-11-08 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7517526B2
(en)
*
|
2000-06-29 |
2009-04-14 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
US6652854B2
(en)
*
|
2000-08-08 |
2003-11-25 |
Immunex Corporation |
Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
|
US9539348B2
(en)
*
|
2000-08-18 |
2017-01-10 |
East Carolina University |
Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
|
EP1328545B1
(en)
*
|
2000-10-18 |
2011-06-22 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Human gene critical to fertility
|
US7090843B1
(en)
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
IL156863A0
(en)
*
|
2001-01-16 |
2004-02-08 |
Genset Sa |
Polynucleotides and polypeptides and their use in metabolic disorders
|
BR0207854A
(pt)
*
|
2001-03-07 |
2004-08-24 |
Merck Patent Gmbh |
Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
JP4309662B2
(ja)
*
|
2001-05-03 |
2009-08-05 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
腫瘍特異的組換え抗体およびその使用
|
WO2003000286A1
(fr)
*
|
2001-06-22 |
2003-01-03 |
Daiichi Suntory Pharma Co., Ltd. |
Remedes pour maladies eosinophiliques
|
WO2003009863A1
(en)
*
|
2001-07-26 |
2003-02-06 |
Genset S.A. |
Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
|
US7270960B2
(en)
*
|
2001-08-29 |
2007-09-18 |
Pacific Northwest Research Institute |
Diagnosis of ovarian carcinomas
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7332474B2
(en)
*
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
MXPA04005266A
(es)
|
2001-12-04 |
2004-10-11 |
Merck Patent Gmbh |
Inmunocitocinas con selectividad modulada.
|
US7786282B2
(en)
|
2001-12-06 |
2010-08-31 |
The Regents Of The University Of California |
Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
|
US7387776B2
(en)
*
|
2002-01-09 |
2008-06-17 |
Medarex, Inc. |
Human monoclonal antibodies against CD30
|
MXPA05002219A
(es)
|
2002-08-28 |
2005-07-05 |
Immunex Corp |
Composiciones y metodos para tratar una enfermedad cardiovascular.
|
CA2510180C
(en)
*
|
2002-12-17 |
2012-09-11 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
TWI353991B
(en)
*
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
AU2004238263A1
(en)
*
|
2003-05-06 |
2004-11-25 |
Syntonix Pharmaceuticals, Inc. |
Inhibition of drug binding to serum albumin
|
EP3552627A1
(en)
*
|
2003-05-06 |
2019-10-16 |
Bioverativ Therapeutics Inc. |
Clotting factor-fc chimeric proteins to treat hemophilia
|
US20050009110A1
(en)
*
|
2003-07-08 |
2005-01-13 |
Xiao-Jia Chang |
Methods of producing antibodies for diagnostics and therapeutics
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
PT1699822E
(pt)
*
|
2003-12-30 |
2008-07-30 |
Merck Patent Gmbh |
Proteínas de fusão de il-7
|
RU2370276C2
(ru)
*
|
2003-12-31 |
2009-10-20 |
Мерк Патент Гмбх |
Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
|
CA2552590A1
(en)
*
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
CA2553187A1
(en)
*
|
2004-01-28 |
2005-08-11 |
Syntonix Pharmaceuticals, Inc. |
Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility
|
AU2004317159B2
(en)
|
2004-02-12 |
2010-12-23 |
The United States Of America, As Represented By Secretary, Department Of Health And Human Services |
Therapeutic administration of the scrambled anti-angiogenic peptide C16Y
|
KR20070034512A
(ko)
|
2004-06-18 |
2007-03-28 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
US8143380B2
(en)
*
|
2004-07-08 |
2012-03-27 |
Amgen Inc. |
Therapeutic peptides
|
US7732131B2
(en)
|
2004-08-03 |
2010-06-08 |
Innate Pharma S.A. |
Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
|
DK1797127T3
(da)
*
|
2004-09-24 |
2017-10-02 |
Amgen Inc |
Modificerede Fc-molekyler
|
AU2005292227A1
(en)
*
|
2004-10-01 |
2006-04-13 |
Medarex, Inc. |
Methods of treating CD30 positive lymphomas
|
EP1819728B1
(en)
*
|
2004-12-09 |
2010-04-21 |
MERCK PATENT GmbH |
Il-7 variants with reduced immunogenicity
|
EP1848745B1
(en)
|
2005-02-18 |
2014-07-09 |
Medarex, L.L.C. |
Monoclonal antibodies against cd30 lacking in fucosyl residues
|
US20090214544A1
(en)
*
|
2005-04-25 |
2009-08-27 |
Medarex |
Method of treating cd30 positive lymphomas
|
WO2006134546A2
(en)
*
|
2005-06-17 |
2006-12-21 |
Koninklijke Philips Electronics N.V. |
Accurate magnetic biosensor
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
TW200722436A
(en)
*
|
2005-10-21 |
2007-06-16 |
Hoffmann La Roche |
A peptide-immunoglobulin-conjugate
|
WO2007084672A2
(en)
*
|
2006-01-17 |
2007-07-26 |
Medarex, Inc. |
Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
|
AU2007208226A1
(en)
*
|
2006-01-25 |
2007-08-02 |
Amgen Inc. |
Thrombopoietic compounds
|
JO3324B1
(ar)
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
US7981425B2
(en)
*
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
KR20120030383A
(ko)
*
|
2009-04-22 |
2012-03-28 |
메르크 파텐트 게엠베하 |
변형된 FcRn 결합 자리를 갖는 항체 융합 단백질
|
ES2598005T3
(es)
|
2009-08-14 |
2017-01-24 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Uso de IL-15 para aumentar la salida del timo y para tratar la linfopenia
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
US9670475B2
(en)
|
2010-07-09 |
2017-06-06 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptides and methods of use thereof
|
KR20140053991A
(ko)
|
2011-07-18 |
2014-05-08 |
아츠 바이올로직스 에이/에스 |
장기간 작용하는 황체 형성 호르몬 (lh) 화합물
|
EP2744828A4
(en)
|
2011-08-16 |
2014-12-31 |
Univ Emory |
JAML-SPECIFIC BINDING AGENTS, ANTIBODIES AND USES THEREOF
|
KR102323287B1
(ko)
|
2011-10-05 |
2021-11-05 |
원드 매터리얼 인코포레이티드 |
리튬 이온 배터리용 실리콘 나노구조체 활물질, 및 그에 관련된 공정, 조성물, 구성요소 및 디바이스
|
US9360414B2
(en)
|
2011-10-14 |
2016-06-07 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Light refraction imaging to measure liquid volume
|
AU2012346056B2
(en)
|
2011-11-29 |
2018-02-22 |
Proclara Biosciences, Inc. |
Use of P3 of bacteriophage as amyloid binding agents
|
CN108324943B
(zh)
*
|
2012-02-10 |
2024-03-08 |
思进股份有限公司 |
Cd30+癌症的检测和治疗
|
EP2841456B1
(en)
*
|
2012-04-27 |
2018-06-13 |
Novo Nordisk A/S |
Human cd30 ligand antigen binding proteins
|
WO2013167750A2
(en)
|
2012-05-11 |
2013-11-14 |
Prorec Bio Ab |
Method for diagnosis and treatment of prolactin associated disorders
|
GB201216649D0
(en)
*
|
2012-09-18 |
2012-10-31 |
Univ Birmingham |
Agents and methods
|
EA033666B1
(ru)
|
2012-10-02 |
2019-11-14 |
Proclara Biosciences Inc |
Амилоидсвязывающие белки и их применение
|
CN103509121B
(zh)
|
2012-11-22 |
2015-01-28 |
苏州康宁杰瑞生物科技有限公司 |
一种fsh融合蛋白及其制备方法和用途
|
WO2014093698A1
(en)
|
2012-12-12 |
2014-06-19 |
The Methodist Hospital Research Institute |
Multi-aptamer-based, cell-specific, one-step tumor cell detection assays
|
CA2899089C
(en)
|
2013-03-15 |
2021-10-26 |
Biogen Ma Inc. |
Factor ix polypeptide formulations
|
MX2015016263A
(es)
|
2013-05-28 |
2016-04-18 |
Neurophage Pharmaceuticals Inc |
Polipeptidos que comprenden una secuencia de aminoacidos de bacteriofago modificado g3p con inmunogenicidad reducida.
|
MX2017007059A
(es)
|
2014-12-03 |
2018-05-02 |
Proclara Biosciences Inc |
Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación.
|
WO2016196344A1
(en)
|
2015-05-30 |
2016-12-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
AU2016349786B2
(en)
|
2015-11-03 |
2023-11-16 |
Ambrx, Inc. |
Anti-CD3-folate conjugates and their uses
|
SG10201601719RA
(en)
|
2016-03-04 |
2017-10-30 |
Agency Science Tech & Res |
Anti-LAG-3 Antibodies
|
SG10201603721TA
(en)
|
2016-05-10 |
2017-12-28 |
Agency Science Tech & Res |
Anti-CTLA-4 Antibodies
|
IT201700084299A1
(it)
|
2017-07-24 |
2019-01-24 |
Univ Degli Studi Padova |
Peptidi derivati dal GAP24 per l’uso nel trattamento della forma X della neuropatia periferica di Charcot-Marie-Tooth
|
WO2020002565A1
(en)
*
|
2018-06-27 |
2020-01-02 |
Sabine Bauer |
Implants for recruiting and removing circulating tumor cells
|
KR20230157356A
(ko)
|
2021-02-17 |
2023-11-16 |
프로메테우스 바이오사이언시즈, 인크. |
항-cd30l 항체 및 이의 용도
|
KR102671409B1
(ko)
*
|
2021-03-02 |
2024-05-31 |
진화섭 |
Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
|
WO2023173084A1
(en)
|
2022-03-11 |
2023-09-14 |
University Of Rochester |
Cyclopeptibodies and uses thereof
|